华讯
/
/
2020-China's Biomedicine Ushers in the Upsurge of Listing

2020-China's Biomedicine Ushers in the Upsurge of Listing

  • 分类:最新消息
  • 作者:华讯知识产权
  • 来源:
  • 发布时间:2020-11-20 13:53
  • 访问量:0

【概要描述】Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies.



Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.



According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:

 





S/N


Company name


Stock Exchange


Capital Raised


Business area




1


Akeso,Inc


HKEx


Over $300 million


Tumour、Autoimmune disease




2


Innocare


HKEx


About HK$2.093 billion


Cancer、Autoimmune disease




3


Kintor Pharmaceutical Limited


HKEx


About $240 million


Prostate Cancer、Breast Cancer

Liver cancer、Baldness




4


Zai Lab Limited


HKEx


HK$5.73 billion


Tumour、Autoimmune disease




5


Immunotech Biopharm Ltd


HKEx


HK$1.0241 billion


T-Cell Immunotherapy




6


Ocumension Therapeutics


HKEx


HK$1.553 billion


Ophthalmology




7


 

Hepalink


HKEx


HK$3.8 billion


Heparin、Tumour




8


Jhbp (Cy) Holdings Limited


HKEx


-----


Tumour、Autoimmune disease




9


Everest Medicines Limited


HKEx


-----


Tumour、Autoimmune disease

Cardiorenal diseases

Infectious disease




10


Simcere Pharmaceutical Group Limited


HKEx


-----


 

Tumour、Central nervous system diseases、Autoimmune disease




11


Jw (Cayman) Therapeutics Co. Ltd


HKEx


-----


CAR-T




12


Remegen Co. Ltd.


HKEx


-----


Autoimmune disease、Tumour

Ophthalmology




13


Antengene Corporation Limited


HKEx


-----


Tumour




14


Zelgen


STAR Market


About ¥2.026 billion


Tumour、Hematopathy

Hepatobiliary disease




15


Bio-Thera Solutions, Ltd


STAR Market


About ¥2.0 billion


Tumour、Autoimmune disease




16


Sinocelltech Grou Limited


STAR Market


About ¥1.282 billion


Monoclonal Antibody

Recombination Protein、Vaccine




17


HitGen Inc.


STAR Market


About ¥830 million


The lead drug




18


Cansino Biologics Inc.


STAR Market


About ¥5.2 billion


Vaccine




19


Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd.


STAR Market


¥3.183 billion


Antibody




20


Jiangsu Aidea Pharmaceutical Co.,ltd


STAR Market


¥839.4 million


Antidote、Tumour




21


Junshi BiosciencesCo., Ltd.


STAR Market


About ¥2.7 billion


Tumour、Chronic disease

Autoimmune disease




22


Easton BioPharmaceuticals Co.,Ltd


STAR Market


¥1.335 billion


Combination of generic drug

development




23


Frontier Biotechnologies Inc


STAR Market


¥1.845 billion


AIDS antiviral treatment.

 Pain therapy





In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD、Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market

2020-China's Biomedicine Ushers in the Upsurge of Listing

【概要描述】Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies.



Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.



According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:

 





S/N


Company name


Stock Exchange


Capital Raised


Business area




1


Akeso,Inc


HKEx


Over $300 million


Tumour、Autoimmune disease




2


Innocare


HKEx


About HK$2.093 billion


Cancer、Autoimmune disease




3


Kintor Pharmaceutical Limited


HKEx


About $240 million


Prostate Cancer、Breast Cancer

Liver cancer、Baldness




4


Zai Lab Limited


HKEx


HK$5.73 billion


Tumour、Autoimmune disease




5


Immunotech Biopharm Ltd


HKEx


HK$1.0241 billion


T-Cell Immunotherapy




6


Ocumension Therapeutics


HKEx


HK$1.553 billion


Ophthalmology




7


 

Hepalink


HKEx


HK$3.8 billion


Heparin、Tumour




8


Jhbp (Cy) Holdings Limited


HKEx


-----


Tumour、Autoimmune disease




9


Everest Medicines Limited


HKEx


-----


Tumour、Autoimmune disease

Cardiorenal diseases

Infectious disease




10


Simcere Pharmaceutical Group Limited


HKEx


-----


 

Tumour、Central nervous system diseases、Autoimmune disease




11


Jw (Cayman) Therapeutics Co. Ltd


HKEx


-----


CAR-T




12


Remegen Co. Ltd.


HKEx


-----


Autoimmune disease、Tumour

Ophthalmology




13


Antengene Corporation Limited


HKEx


-----


Tumour




14


Zelgen


STAR Market


About ¥2.026 billion


Tumour、Hematopathy

Hepatobiliary disease




15


Bio-Thera Solutions, Ltd


STAR Market


About ¥2.0 billion


Tumour、Autoimmune disease




16


Sinocelltech Grou Limited


STAR Market


About ¥1.282 billion


Monoclonal Antibody

Recombination Protein、Vaccine




17


HitGen Inc.


STAR Market


About ¥830 million


The lead drug




18


Cansino Biologics Inc.


STAR Market


About ¥5.2 billion


Vaccine




19


Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd.


STAR Market


¥3.183 billion


Antibody




20


Jiangsu Aidea Pharmaceutical Co.,ltd


STAR Market


¥839.4 million


Antidote、Tumour




21


Junshi BiosciencesCo., Ltd.


STAR Market


About ¥2.7 billion


Tumour、Chronic disease

Autoimmune disease




22


Easton BioPharmaceuticals Co.,Ltd


STAR Market


¥1.335 billion


Combination of generic drug

development




23


Frontier Biotechnologies Inc


STAR Market


¥1.845 billion


AIDS antiviral treatment.

 Pain therapy





In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTD、Changchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market

  • 分类:最新消息
  • 作者:华讯知识产权
  • 来源:
  • 发布时间:2020-11-20 13:53
  • 访问量:0
详情

Affected by the COVID-19, global IPO activity slows down in 2020. But this year is a glorious year for China's biomedical companies.

Since 2018, the Hong Kong Exchanges and Clearing Limited (HKEx) has opened its doors for the first time to biotechnology companies that have no operating income. In 2019, The Science and Technology Innovation Board (STAR Market) established by the Shanghai Stock Exchange has been officially opened for trading. It has brought new vitality to China's capital market and the development of China's technology.. The HKEx and STAR Market have become the first choice for many Chinese unprofitable biomedical companies to list.

According to incomplete statistics, as of Nov 20, at least 13 Chinese biopharmaceutical companies have been listed on the HKEx and 10 companies have been listed on the STAR Market. See the table below for details:

 

S/N

Company name

Stock Exchange

Capital Raised

Business area

1

Akeso,Inc

HKEx

Over $300 million

TumourAutoimmune disease

2

Innocare

HKEx

About HK$2.093 billion

CancerAutoimmune disease

3

Kintor Pharmaceutical Limited

HKEx

About $240 million

Prostate CancerBreast Cancer

Liver cancerBaldness

4

Zai Lab Limited

HKEx

HK$5.73 billion

TumourAutoimmune disease

5

Immunotech Biopharm Ltd

HKEx

HK$1.0241 billion

T-Cell Immunotherapy

6

Ocumension Therapeutics

HKEx

HK$1.553 billion

Ophthalmology

7

 

Hepalink

HKEx

HK$3.8 billion

HeparinTumour

8

Jhbp (Cy) Holdings Limited

HKEx

-----

TumourAutoimmune disease

9

Everest Medicines Limited

HKEx

-----

TumourAutoimmune disease

Cardiorenal diseases

Infectious disease

10

Simcere Pharmaceutical Group Limited

HKEx

-----

 

TumourCentral nervous system diseasesAutoimmune disease

11

Jw (Cayman) Therapeutics Co. Ltd

HKEx

-----

CAR-T

12

Remegen Co. Ltd.

HKEx

-----

Autoimmune diseaseTumour

Ophthalmology

13

Antengene Corporation Limited

HKEx

-----

Tumour

14

Zelgen

STAR Market

About ¥2.026 billion

TumourHematopathy

Hepatobiliary disease

15

Bio-Thera Solutions, Ltd

STAR Market

About ¥2.0 billion

TumourAutoimmune disease

16

Sinocelltech Grou Limited

STAR Market

About ¥1.282 billion

Monoclonal Antibody

Recombination ProteinVaccine

17

HitGen Inc.

STAR Market

About ¥830 million

The lead drug

18

Cansino Biologics Inc.

STAR Market

About ¥5.2 billion

Vaccine

19

Sunshine Guojian Pharmaceutical(shanghai) Co. Ltd.

STAR Market

¥3.183 billion

Antibody

20

Jiangsu Aidea Pharmaceutical Co.,ltd

STAR Market

¥839.4 million

AntidoteTumour

21

Junshi BiosciencesCo., Ltd.

STAR Market

About ¥2.7 billion

TumourChronic disease

Autoimmune disease

22

Easton BioPharmaceuticals Co.,Ltd

STAR Market

¥1.335 billion

Combination of generic drug

development

23

Frontier Biotechnologies Inc

STAR Market

¥1.845 billion

AIDS antiviral treatment.

 Pain therapy

In addition to the companies listed in the above table, other biopharmaceutical companies such as Beijing Science Sun Pharmaceutical Co.,LTDChangchun BCHT Biotechnology Co and other companies have also submitted IPO applications to the HKEx and the STAR Market

关键词:

扫二维码用手机看

CONTACT

电话:+86 25 56673162 
E-Mail:service@chinaipic.com
地址:江苏省南京市江北新区江淼路88号腾飞大厦B座20层2001

公众号二维码

扫一扫,关注我们微博

公众号二维码

扫一扫,关注我们公众号

版权所有 © 南京华讯知识产权顾问有限公司      备案号:苏ICP备15002104号-1      网站建设:中企动力  南京